Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 25 entries
Sorted by: Best Match Show Resources per page
Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study.

Journal of clinical and translational hepatology

Flamm SL, Pockros PJ, Bengtsson L, Friedman M.
PMID: 26356545
J Clin Transl Hepatol. 2014 Jun;2(2):65-73. doi: 10.14218/JCTH.2014.00007. Epub 2014 Jun 15.

BACKGROUND AND AIMS: There is a paucity of information regarding similarities and differences between patients from the phase 3 studies of telaprevir and those receiving telaprevir in clinical practice.METHODS: This retrospective chart review evaluated baseline characteristics and follow-up safety...

Cite
Flamm SL, Pockros PJ, Bengtsson L, et al. Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study. J Clin Transl Hepatol. 2014;2(2):65-73doi: 10.14218/JCTH.2014.00007.
Flamm, S. L., Pockros, P. J., Bengtsson, L., & Friedman, M. (2014). Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study. Journal of clinical and translational hepatology, 2(2), 65-73. https://doi.org/10.14218/JCTH.2014.00007
Flamm, Steven L, et al. "Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study." Journal of clinical and translational hepatology vol. 2,2 (2014): 65-73. doi: https://doi.org/10.14218/JCTH.2014.00007
Flamm SL, Pockros PJ, Bengtsson L, Friedman M. Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study. J Clin Transl Hepatol. 2014 Jun;2(2):65-73. doi: 10.14218/JCTH.2014.00007. Epub 2014 Jun 15. PMID: 26356545; PMCID: PMC4521261.
Copy Download .nbib Format: NLM
How should hepatitis C be managed in patients aged 65 years and older?.

Nature clinical practice. Gastroenterology & hepatology

Nourani S, Pockros PJ.
PMID: 17203085
Nat Clin Pract Gastroenterol Hepatol. 2007 Jan;4(1):22-3. doi: 10.1038/ncpgasthep0682.

No abstract available.

Cite
Nourani S, Pockros PJ. How should hepatitis C be managed in patients aged 65 years and older?. Nat Clin Pract Gastroenterol Hepatol. 2007;4(1):22-3doi: 10.1038/ncpgasthep0682.
Nourani, S., & Pockros, P. J. (2007). How should hepatitis C be managed in patients aged 65 years and older?. Nature clinical practice. Gastroenterology & hepatology, 4(1), 22-3. https://doi.org/10.1038/ncpgasthep0682
Nourani, Sam, and Pockros, Paul J. "How should hepatitis C be managed in patients aged 65 years and older?." Nature clinical practice. Gastroenterology & hepatology vol. 4,1 (2007): 22-3. doi: https://doi.org/10.1038/ncpgasthep0682
Nourani S, Pockros PJ. How should hepatitis C be managed in patients aged 65 years and older?. Nat Clin Pract Gastroenterol Hepatol. 2007 Jan;4(1):22-3. doi: 10.1038/ncpgasthep0682. PMID: 17203085.
Copy Download .nbib Format: NLM
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease.

Kidney international reports

Bernstein DE, Tran A, Martin P, Kowdley KV, Bourliere M, Sulkowski MS, Pockros PJ, Renjifo B, Wang D, Shuster DL, Cohen DE, Jacobson IM.
PMID: 30775621
Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb.

INTRODUCTION: Patients with hepatitis C virus (HCV) infection and chronic kidney disease (CKD) are a high-priority population for treatment.METHODS: We performed a RESULTS: SVR12 rates in patients with stage 1, 2, and 3 CKD were 97% (439/453), 98% (536/547),...

Cite
Bernstein DE, Tran A, Martin P, et al. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease. Kidney Int Rep. 2018;4(2):245-256doi: 10.1016/j.ekir.2018.10.005.
Bernstein, D. E., Tran, A., Martin, P., Kowdley, K. V., Bourliere, M., Sulkowski, M. S., Pockros, P. J., Renjifo, B., Wang, D., Shuster, D. L., Cohen, D. E., & Jacobson, I. M. (2019). Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease. Kidney international reports, 4(2), 245-256. https://doi.org/10.1016/j.ekir.2018.10.005
Bernstein, David E, et al. "Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease." Kidney international reports vol. 4,2 (2019): 245-256. doi: https://doi.org/10.1016/j.ekir.2018.10.005
Bernstein DE, Tran A, Martin P, Kowdley KV, Bourliere M, Sulkowski MS, Pockros PJ, Renjifo B, Wang D, Shuster DL, Cohen DE, Jacobson IM. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease. Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb. PMID: 30775621; PMCID: PMC6365509.
Copy Download .nbib Format: NLM
Pulmonary complications of transcatheter arterial chemoembolization for hepatocellular carcinoma.

World journal of respirology

Nhu QM, Knowles H, Pockros PJ, Frenette CT.
PMID: 27904836
World J Respirol. 2016;6(3):69-75. doi: 10.5320/WJR.v6.i3.69. Epub 2016 Nov 28.

Transarterial chemoembolization (TACE) is an effective palliative intervention that is widely accepted for the management of hepatocellular carcinoma (HCC). Post-TACE pulmonary complications resulting in acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) are rare events. Pulmonary complications...

Cite
Nhu QM, Knowles H, Pockros PJ, et al. Pulmonary complications of transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Respirol. 2016;6(3):69-75doi: 10.5320/WJR.v6.i3.69.
Nhu, Q. M., Knowles, H., Pockros, P. J., & Frenette, C. T. (2016). Pulmonary complications of transcatheter arterial chemoembolization for hepatocellular carcinoma. World journal of respirology, 6(3), 69-75. https://doi.org/10.5320/WJR.v6.i3.69
Nhu, Quan M, et al. "Pulmonary complications of transcatheter arterial chemoembolization for hepatocellular carcinoma." World journal of respirology vol. 6,3 (2016): 69-75. doi: https://doi.org/10.5320/WJR.v6.i3.69
Nhu QM, Knowles H, Pockros PJ, Frenette CT. Pulmonary complications of transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Respirol. 2016;6(3):69-75. doi: 10.5320/WJR.v6.i3.69. Epub 2016 Nov 28. PMID: 27904836; PMCID: PMC5125773.
Copy Download .nbib Format: NLM
Genotype 3: Treat now or wait for something better?.

Clinical liver disease

Pockros PJ.
PMID: 31041008
Clin Liver Dis (Hoboken). 2015 Dec 09;6(5):129-131. doi: 10.1002/cld.510. eCollection 2015 Nov.

No abstract available.

Cite
Pockros PJ. Genotype 3: Treat now or wait for something better?. Clin Liver Dis (Hoboken). 2015;6(5):129-131doi: 10.1002/cld.510.
Pockros, P. J. (2015). Genotype 3: Treat now or wait for something better?. Clinical liver disease, 6(5), 129-131. https://doi.org/10.1002/cld.510
Pockros, Paul J. "Genotype 3: Treat now or wait for something better?." Clinical liver disease vol. 6,5 (2015): 129-131. doi: https://doi.org/10.1002/cld.510
Pockros PJ. Genotype 3: Treat now or wait for something better?. Clin Liver Dis (Hoboken). 2015 Dec 09;6(5):129-131. doi: 10.1002/cld.510. eCollection 2015 Nov. PMID: 31041008; PMCID: PMC6490668.
Copy Download .nbib Format: NLM
System-Wide Echocardiography Accreditation: Physician Perceptions and Concerns.

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography

Pockros B, Balamurugan A, Radparvar J, Chilingerian JA, Cohen M.
PMID: 31864771
J Am Soc Echocardiogr. 2020 Feb;33(2):255-256. doi: 10.1016/j.echo.2019.09.021. Epub 2019 Dec 19.

No abstract available.

Cite
Pockros B, Balamurugan A, Radparvar J, et al. System-Wide Echocardiography Accreditation: Physician Perceptions and Concerns. J Am Soc Echocardiogr. 2019;33(2):255-256doi: 10.1016/j.echo.2019.09.021.
Pockros, B., Balamurugan, A., Radparvar, J., Chilingerian, J. A., & Cohen, M. (2020). System-Wide Echocardiography Accreditation: Physician Perceptions and Concerns. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 33(2), 255-256. https://doi.org/10.1016/j.echo.2019.09.021
Pockros, Benjamin, et al. "System-Wide Echocardiography Accreditation: Physician Perceptions and Concerns." Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography vol. 33,2 (2020): 255-256. doi: https://doi.org/10.1016/j.echo.2019.09.021
Pockros B, Balamurugan A, Radparvar J, Chilingerian JA, Cohen M. System-Wide Echocardiography Accreditation: Physician Perceptions and Concerns. J Am Soc Echocardiogr. 2020 Feb;33(2):255-256. doi: 10.1016/j.echo.2019.09.021. Epub 2019 Dec 19. PMID: 31864771.
Copy Download .nbib Format: NLM
Update on the Treatment of Hepatitis C Virus Infection in Patients With Cirrhosis.

Gastroenterology & hepatology

Pockros PJ.
PMID: 31802987
Gastroenterol Hepatol (N Y). 2019 Nov;15(11):616-618.

No abstract available.

Cite
Pockros PJ. Update on the Treatment of Hepatitis C Virus Infection in Patients With Cirrhosis. Gastroenterol Hepatol (N Y). 2019;15(11):616-618
Pockros, P. J. (2019). Update on the Treatment of Hepatitis C Virus Infection in Patients With Cirrhosis. Gastroenterology & hepatology, 15(11), 616-618.
Pockros, Paul J. "Update on the Treatment of Hepatitis C Virus Infection in Patients With Cirrhosis." Gastroenterology & hepatology vol. 15,11 (2019): 616-618.
Pockros PJ. Update on the Treatment of Hepatitis C Virus Infection in Patients With Cirrhosis. Gastroenterol Hepatol (N Y). 2019 Nov;15(11):616-618. PMID: 31802987; PMCID: PMC6883731.
Copy Download .nbib Format: NLM
Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel.

BMJ open gastroenterology

Pate J, Gutierrez JA, Frenette CT, Goel A, Kumar S, Manch RA, Mena EA, Pockros PJ, Satapathy SK, Yimam KK, Gish RG.
PMID: 30815273
BMJ Open Gastroenterol. 2019 Feb 01;6(1):e000256. doi: 10.1136/bmjgast-2018-000256. eCollection 2019.

BACKGROUND AND AIMS: This article provides expert guidance on the management of pruritus symptoms in patients receiving obeticholic acid (OCA) as treatment for primary biliary cholangitis (PBC). PBC is a chronic, autoimmune cholestatic liver disease that affects intrahepatic bile...

Cite
Pate J, Gutierrez JA, Frenette CT, et al. Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. BMJ Open Gastroenterol. 2019;6(1):e000256doi: 10.1136/bmjgast-2018-000256.
Pate, J., Gutierrez, J. A., Frenette, C. T., Goel, A., Kumar, S., Manch, R. A., Mena, E. A., Pockros, P. J., Satapathy, S. K., Yimam, K. K., & Gish, R. G. (2019). Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. BMJ open gastroenterology, 6(1), e000256. https://doi.org/10.1136/bmjgast-2018-000256
Pate, Jennifer, et al. "Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel." BMJ open gastroenterology vol. 6,1 (2019): e000256. doi: https://doi.org/10.1136/bmjgast-2018-000256
Pate J, Gutierrez JA, Frenette CT, Goel A, Kumar S, Manch RA, Mena EA, Pockros PJ, Satapathy SK, Yimam KK, Gish RG. Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. BMJ Open Gastroenterol. 2019 Feb 01;6(1):e000256. doi: 10.1136/bmjgast-2018-000256. eCollection 2019. PMID: 30815273; PMCID: PMC6361341.
Copy Download .nbib Format: NLM
Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection.

Gastroenterology & hepatology

Pockros PJ.
PMID: 29038644
Gastroenterol Hepatol (N Y). 2017 Sep;13(9):536-540.

In 2016, the US Food and Drug Administration issued a warning about the risk of hepatitis B virus (HBV) reactivation in some patients receiving direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection. HBV reactivation can occur soon...

Cite
Pockros PJ. Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection. Gastroenterol Hepatol (N Y). 2017;13(9):536-540
Pockros, P. J. (2017). Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection. Gastroenterology & hepatology, 13(9), 536-540.
Pockros, Paul J. "Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection." Gastroenterology & hepatology vol. 13,9 (2017): 536-540.
Pockros PJ. Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection. Gastroenterol Hepatol (N Y). 2017 Sep;13(9):536-540. PMID: 29038644; PMCID: PMC5635429.
Copy Download .nbib Format: NLM
New direct-acting antivirals in the development for hepatitis C virus infection.

Therapeutic advances in gastroenterology

Pockros PJ.
PMID: 21180601
Therap Adv Gastroenterol. 2010 May;3(3):191-202. doi: 10.1177/1756283X10363055.

A large number of new therapies are in development for chronic hepatitis C including direct-acting antiviral drugs (DAA), which target specific hepatitis C virus enzymes. Two of these compounds have already advanced into phase 3 development in the USA...

Cite
Pockros PJ. New direct-acting antivirals in the development for hepatitis C virus infection. Therap Adv Gastroenterol. 2010;3(3):191-202doi: 10.1177/1756283X10363055.
Pockros, P. J. (2010). New direct-acting antivirals in the development for hepatitis C virus infection. Therapeutic advances in gastroenterology, 3(3), 191-202. https://doi.org/10.1177/1756283X10363055
Pockros, Paul J. "New direct-acting antivirals in the development for hepatitis C virus infection." Therapeutic advances in gastroenterology vol. 3,3 (2010): 191-202. doi: https://doi.org/10.1177/1756283X10363055
Pockros PJ. New direct-acting antivirals in the development for hepatitis C virus infection. Therap Adv Gastroenterol. 2010 May;3(3):191-202. doi: 10.1177/1756283X10363055. PMID: 21180601; PMCID: PMC3002578.
Copy Download .nbib Format: NLM
Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology.

The Prostate

Pockros B, Stensland KD, Parries M, Frankenberger E, Canes D, Moinzadeh A.
PMID: 34878175
Prostate. 2021 Dec 08; doi: 10.1002/pros.24280. Epub 2021 Dec 08.

INTRODUCTION: Prostate Imaging Reporting and Data System (PI-RADS) scores can help identify clinically significant prostate cancer and improve patient selection for prostate biopsies. However, the role of PI-RADS scores in patients already diagnosed with prostate cancer remains unclear. The...

Cite
Pockros B, Stensland KD, Parries M, et al. Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology. Prostate. 2021;doi: 10.1002/pros.24280.
Pockros, B., Stensland, K. D., Parries, M., Frankenberger, E., Canes, D., & Moinzadeh, A. (2021). Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology. The Prostate, . https://doi.org/10.1002/pros.24280
Pockros, Benjamin, et al. "Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology." The Prostate vol. (2021). doi: https://doi.org/10.1002/pros.24280
Pockros B, Stensland KD, Parries M, Frankenberger E, Canes D, Moinzadeh A. Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology. Prostate. 2021 Dec 08; doi: 10.1002/pros.24280. Epub 2021 Dec 08. PMID: 34878175.
Copy Download .nbib Format: NLM
Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology.

The Prostate

Pockros B, Stensland KD, Parries M, Frankenberger E, Canes D, Moinzadeh A.
PMID: 34878175
Prostate. 2022 Feb;82(3):352-358. doi: 10.1002/pros.24280. Epub 2021 Dec 08.

INTRODUCTION: Prostate Imaging Reporting and Data System (PI-RADS) scores can help identify clinically significant prostate cancer and improve patient selection for prostate biopsies. However, the role of PI-RADS scores in patients already diagnosed with prostate cancer remains unclear. The...

Cite
Pockros B, Stensland KD, Parries M, et al. Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology. Prostate. 2021;82(3):352-358doi: 10.1002/pros.24280.
Pockros, B., Stensland, K. D., Parries, M., Frankenberger, E., Canes, D., & Moinzadeh, A. (2022). Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology. The Prostate, 82(3), 352-358. https://doi.org/10.1002/pros.24280
Pockros, Benjamin, et al. "Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology." The Prostate vol. 82,3 (2022): 352-358. doi: https://doi.org/10.1002/pros.24280
Pockros B, Stensland KD, Parries M, Frankenberger E, Canes D, Moinzadeh A. Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology. Prostate. 2022 Feb;82(3):352-358. doi: 10.1002/pros.24280. Epub 2021 Dec 08. PMID: 34878175.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 25 entries